The breakthrough you’re asking about refers to AMT-130, an experimental one-time gene therapy developed by the Dutch biotech company uniQure in collaboration with UK researchers. Announced on September 24, 2025, it represents the first treatment shown to significantly slow the progression of Huntington’s disease (HD), a rare, inherited neurodegenerative disorder. This is a landmark achievement, as no prior therapies have demonstrated disease-modifying effects—only symptom management. Below, I’ll break down the key details, drawing from the phase I/II clinical trial results.
What is Huntington’s Disease?
HD is caused by a mutation in the HTT gene, discovered in 1993 by UK researchers including Prof. Gillian Bates at King’s College London. This mutation leads to an expanded CAG repeat sequence, producing a toxic form of the huntingtin protein that gradually damages neurons in the brain, particularly in the striatum (involved in movement and cognition). Symptoms typically emerge in a person’s 30s or 40s, including involuntary movements (chorea), cognitive decline, psychiatric issues, and eventual dementia and paralysis. It’s fatal within 15–20 years of onset, with no cure. If a parent has HD, there’s a 50% chance of inheritance. Globally, it affects ~75,000 people in the UK, US, and Europe, plus hundreds of thousands of carriers.
How Does AMT-130 Work?
AMT-130 uses an adeno-associated virus (AAV) vector—a harmless, engineered virus—to deliver genetic instructions directly into the brain. These instructions encode a microRNA that “silences” the mutant HTT gene, reducing production of the toxic huntingtin protein by up to 70% in targeted areas like the caudate nucleus and putamen. Unlike CRISPR-based edits, this is a silencing approach, preserving the normal huntingtin protein (essential for brain function) while targeting the mutant allele.
The therapy is administered via a single surgical procedure: Under MRI guidance, surgeons drill small holes in the skull and infuse the virus through catheters into the brain, taking 12–18 hours. It’s designed to be permanent, as brain cells don’t regenerate like other tissues, potentially providing lifelong benefits.
The Clinical Trial: Key Results
The phase I/II trial (UNITE-HD) enrolled 39 early-stage HD patients (manifesting symptoms but not severely advanced) across sites in the US, UK (UCLH and Cardiff), and Europe. Participants received either a low or high dose of AMT-130; results focused on 24 high-dose patients followed for up to 36 months, compared to a matched cohort of ~1,600 untreated HD patients from the Enroll-HD natural history study.
| Metric | High-Dose AMT-130 (n=12 at 36 months) | Untreated Control | Improvement |
|---|---|---|---|
| Composite Unified Huntington’s Disease Rating Scale (cUHDRS) (overall progression: motor, cognitive, functional) | -0.38 points decline | -1.52 points decline | 75% slower progression |
| Total Functional Capacity (TFC) (daily living independence) | Minimal decline | Expected 20–30% worsening | Statistically significant stabilization |
| Neurofilament Light Chain (NfL) (biomarker of neuron damage in spinal fluid) | Remained below baseline (no increase) | Expected 20–30% rise | Indicates reduced brain cell death |
| Motor & Cognitive Scores (e.g., chorea, balance, memory) | 50–60% less decline | Standard progression | Dose-dependent benefits |
These results suggest that what would normally take 1 year of decline now takes ~4 years post-treatment, potentially adding decades of quality life. One patient even returned to work after medical retirement due to HD. Low-dose results were less consistent, supporting a dose-response effect.
Safety and Side Effects
AMT-130 was generally well-tolerated, with a “manageable” safety profile. Common issues included surgical risks (e.g., headache, swelling) and mild immune responses to the virus, but no serious adverse events linked to the therapy. Long-term monitoring continues, as gene therapies can have delayed effects.
Impact and Patient Stories
“This changes everything,” said Prof. Ed Wild, principal investigator at UCL’s Huntington’s Disease Centre. Patients like Jack May-Davis (30, from Sussex, gene carrier since age 19) called it a “huge moment,” noting it could extend independent living for families devastated by HD. Support worker Kerry Perry (Liverpool) shared tears of joy with her community, hoping for future access despite her mild symptoms. Prof. Sarah Tabrizi, trial lead at UCL and UK Dementia Research Institute, described it as “spectacular,” emphasizing its potential to prevent symptoms if given pre-onset.
Next Steps and Challenges
UniQure plans FDA accelerated approval submission in early 2026, followed by UK/EU applications. Larger phase III trials are needed for full licensing. Challenges include:
- Cost: Gene therapies can exceed $1M+ per dose; affordability models (e.g., payment over time) are being explored.
- Access: Requires specialized neurosurgery (only a few UK sites like UCLH/Cardiff equipped).
- Limitations: Small trial (not yet peer-reviewed); not tested in advanced HD or pre-symptomatic carriers. Ethical concerns around irreversible brain delivery.
This builds on decades of UK-led HD research, including the first huntingtin-lowering trial in 2015. It’s a proof-of-concept for gene silencing in neurodegeneration, potentially inspiring treatments for similar diseases like ALS or Parkinson’s. For more, see UCL’s updates or HDBuzz for patient-focused analysis. If you’d like details on related trials (e.g., allele-selective editing), let me know!
